Beam CLO auto-sells shares to cover RSU taxes

Beam Therapeutics Inc. Chief Legal Officer Christine Bellon reported an automatic sale of 5,956 shares of common stock on April 1, 2026 at $24.58 per share.

Rhea-AI Filing Summary

Beam Therapeutics Inc. Chief Legal Officer Christine Bellon reported an automatic sale of 5,956 shares of common stock on April 1, 2026 at $24.58 per share. After this transaction, she directly holds 109,711 shares of Beam Therapeutics common stock.

The shares were sold in a non-discretionary transaction solely to cover tax withholding obligations arising from the vesting of restricted stock units granted on March 31 of 2022, 2023, 2024 and 2025 under the company’s 2019 Equity Incentive Plan. The sales were effected under a Rule 10b5-1 trading plan adopted on May 19, 2023, indicating the trades were pre-planned rather than opportunistic market sales.

Insider Trade Summary 10b5-1

Net Seller: 5,956 shares

Net Sell 1 txn

Insider Bellon Christine

Role Chief Legal Officer

Sold 5,956 shs ($146K)

Type	Security	Shares	Price	Value
Sale	Common Stock	5,956	$24.58	$146K

Holdings After Transaction: Common Stock — 109,711 shares (Direct)

Footnotes (1)

1. F1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

Key Figures

Shares sold: 5,956 shares Sale price per share: $24.58/share Shares held after transaction: 109,711 shares +1 more

4 metrics

Shares sold 5,956 shares Automatic sale on April 1, 2026 to cover tax withholding

Sale price per share $24.58/share Price for Beam Therapeutics common stock in this transaction

Shares held after transaction 109,711 shares Direct ownership by Christine Bellon following the sale

RSU vesting dates March 31, 2022, 2023, 2024, 2025 Vesting of RSUs that created tax obligations

Key Terms

restricted stock units, 2019 Equity Incentive Plan, Rule 10b5-1 trading plan, tax withholding obligations

4 terms

restricted stock units financial

"upon the vesting of certain restricted stock units granted to the Reporting Person"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2019 Equity Incentive Plan financial

"granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan"

Rule 10b5-1 trading plan regulatory

"The sales were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

tax withholding obligations financial

"sold in a non-discretionary transaction ... to cover tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Beam Therapeutics (BEAM) report for Christine Bellon?

Beam Therapeutics reported that Chief Legal Officer Christine Bellon automatically sold 5,956 shares of common stock. The transaction occurred on April 1, 2026 at $24.58 per share and was tied to tax withholding on vesting restricted stock units.

Why did Beam Therapeutics CLO Christine Bellon sell 5,956 BEAM shares?

The 5,956 shares were sold automatically to cover tax withholding obligations from vesting restricted stock units. These RSUs were granted under Beam Therapeutics’ 2019 Equity Incentive Plan and vested on March 31 in 2022, 2023, 2024 and 2025.

Was Christine Bellon’s BEAM share sale part of a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 trading plan adopted by Christine Bellon on May 19, 2023. Such plans pre-schedule trades, indicating the timing was planned rather than a discretionary market decision.

How many Beam Therapeutics shares does Christine Bellon hold after this transaction?

Following the April 1, 2026 transaction, Christine Bellon directly holds 109,711 shares of Beam Therapeutics common stock. This figure comes from the post-transaction ownership line in the Form 4, showing her remaining equity stake after the tax-related sale.

What equity awards triggered the tax-withholding sale for BEAM’s Chief Legal Officer?

The tax-withholding sale was triggered by vesting of restricted stock units granted under Beam Therapeutics’ 2019 Equity Incentive Plan. These RSUs vested on March 31 of 2022, 2023, 2024 and 2025, creating tax obligations that the automatic share sale helped satisfy.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/06/2026 - 05:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bellon Christine

(Last) (First) (Middle)

C/O BEAM THERAPEUTICS INC.,

238 MAIN STREET

(Street)

CAMBRIDGE MASSACHUSETTS 02142

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Beam Therapeutics Inc. [ BEAM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Legal Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	04/01/2026		S(1)		5,956	D	$24.58	109,711	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. These shares of common stock were automatically sold in a non-discretionary transaction by the Reporting Person in order to cover tax withholding obligations upon the vesting of certain restricted stock units granted to the Reporting Person under the Beam Therapeutics Inc. 2019 Equity Incentive Plan on each of March 31, 2022, March 31, 2023, March 31, 2024 and March 31, 2025. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 19, 2023.

	By: /s/ Christine Bellon	04/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)